South Korea
· Delayed Price · Currency is KRW Prestige Biologics Statistics
Total Valuation
Prestige Biologics has a market cap or net worth of KRW 375.77 billion. The enterprise value is 519.31 billion.
| Market Cap | 375.77B |
| Enterprise Value | 519.31B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Prestige Biologics has 61.50 million shares outstanding. The number of shares has increased by 23.38% in one year.
| Shares Outstanding | 61.50M |
| Shares Change (YoY) | +23.38% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 25.98% |
| Owned by Institutions (%) | 0.02% |
| Float | 8.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 172.56 |
| PB Ratio | 5.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.68 |
| EV / Sales | 239.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.79 |
Financial Position
The company has a current ratio of 0.60, with a Debt / Equity ratio of 2.41.
| Current Ratio | 0.60 |
| Quick Ratio | 0.34 |
| Debt / Equity | 2.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -10.26 |
| Interest Coverage | -2.84 |
Financial Efficiency
Return on equity (ROE) is -34.26% and return on invested capital (ROIC) is -8.28%.
| Return on Equity (ROE) | -34.26% |
| Return on Assets (ROA) | -7.02% |
| Return on Capital (ROIC) | -8.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +31.13% |
| 50-Day Moving Average | 5,891.90 |
| 200-Day Moving Average | 4,754.48 |
| Relative Strength Index (RSI) | 53.37 |
| Average Volume (20 Days) | 481,349 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Prestige Biologics had revenue of KRW 2.17 billion and -29.37 billion in losses. Loss per share was -479.50.
| Revenue | 2.17B |
| Gross Profit | -8.84B |
| Operating Income | -33.43B |
| Pretax Income | -29.37B |
| Net Income | -29.37B |
| EBITDA | -22.20B |
| EBIT | -33.43B |
| Loss Per Share | -479.50 |
Balance Sheet
The company has 29.51 billion in cash and 173.04 billion in debt, giving a net cash position of -143.54 billion or -2,333.86 per share.
| Cash & Cash Equivalents | 29.51B |
| Total Debt | 173.04B |
| Net Cash | -143.54B |
| Net Cash Per Share | -2,333.86 |
| Equity (Book Value) | 71.68B |
| Book Value Per Share | 1,165.54 |
| Working Capital | -36.67B |
Cash Flow
In the last 12 months, operating cash flow was -8.35 billion and capital expenditures -8.52 billion, giving a free cash flow of -16.87 billion.
| Operating Cash Flow | -8.35B |
| Capital Expenditures | -8.52B |
| Free Cash Flow | -16.87B |
| FCF Per Share | -274.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,541.23% |
| Pretax Margin | -1,354.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -777.63% |
Dividends & Yields
Prestige Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.38% |
| Shareholder Yield | -23.38% |
| Earnings Yield | -7.85% |
| FCF Yield | -4.49% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prestige Biologics has an Altman Z-Score of -0.82. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.82 |
| Piotroski F-Score | n/a |